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Background: Globally, bronchopulmonary dysplasia (BPD) continues to increase in preterm infants. 
Recent studies exploring subsequent early childhood respiratory morbidity have been small or focused 
on hospital admissions.  
 
Primary aim: Examine early childhood rates of primary care consultations for respiratory tract 
infections (RTI), lower respiratory tract infections (LRTI), wheeze and antibiotic prescriptions (Abx 
Px) in ex-preterm and term children. Secondary aim: examine differences between preterm infants 
discharged home with or without oxygen. 
 
Methods: Retrospective cohort study using linked electronic primary care and hospital databases of 
children born between 1997 to 2014. We included 253,277 eligible children, with 1,666 born preterm 
<32 weeks’ gestation, followed up from primary care registration to age 5 years. Adjusted incidence 
rate ratios (aIRR) were calculated. 
 
Results: Ex-preterm infants had higher rates of morbidity across all respiratory outcomes. After 
adjusting for confounders, aIRRs for RTI (1.37, 95% CI 1.33-1.42), LRTI (2.79, 95% CI 2.59-3.01), 
wheeze (3.05, 95% CI 2.64-3.52) and Abx Px (1.49, 95% CI 1.44-1.55) were higher for ex-preterm 
infants. Ex-preterm infants discharged home on oxygen had significantly greater morbidity across all 
respiratory diagnoses and Abx Px compared to those without home oxygen.  The highest rates of 
respiratory morbidity were observed in children from the most deprived socioeconomic groups.   
 
Conclusion: Ex-preterm infants, particularly those with BPD requiring home oxygen, have significant 
respiratory morbidity and antibiotic prescriptions in early childhood.  With the increasing prevalence 
of BPD, further research should focus on strategies to reduce the burden of respiratory morbidity in 






Survival of preterm, very low birth weight (VLBW) infants has improved with the introduction of 
antenatal corticosteroids, surfactant administration, along with better nutrition and ventilation 
strategies [1–4]. However, the incidence of bronchopulmonary dysplasia (BPD), a chronic respiratory 
condition of prematurity, continues to increase and is a major cause of long-term morbidity and 
mortality in preterm survivors [5–7]. In Europe, the prevalence of BPD in infants born before 32 
weeks gestational age (GA) has increased from 23.3% (2007-11) to 27.5% (2012-15) [8], equating to 
approximately 28,000 affected preterm infants annually based on current birth rates [9]. In the USA, 
current annual estimates of new cases of BPD range between 10,000-15,000 [10, 11].  
 
BPD is associated with long-term adult respiratory morbidity, including asthma and chronic 
obstructive pulmonary disease [3, 12, 13].  In the UK, guidance on post-discharge follow-up for 
respiratory management in preterm infants with BPD is only provided for those requiring home 
oxygen, omitting a larger group with less severe BPD [14]. Moreover, there is need to explore 
additional periods in early life which are potentially amenable to alterations of the adverse respiratory 
trajectory and hence reduce long-term morbidities. One potential roadblock to achieving these goals is 
the lack of recent, nationally representative data on early childhood respiratory morbidity in preterm 
survivors outside of the hospital setting. Greenough and colleagues studied ex-preterm infants and 
provided many useful insights into their respiratory health [15].  However, this small study of infants 
born in 1994-97 did not provide respiratory diagnoses or antibiotic use, had no term comparison 
group and follow-up stopped at two years of age.  A larger, more contemporary study with a term 
comparator group may provide important information on the respiratory outcomes of these children 
and identify disparities to be further explored in future research [16][17].   
 
We hypothesised that ex-preterm infants have increased respiratory morbidity in early childhood. The 
primary aim of our study was to quantify early childhood respiratory morbidity in preterm survivors 
compared to their term-born counterparts. The secondary aims were to examine differences between 







This is a retrospective cohort study, using data obtained from the Clinical Practice Research Datalink 
(CPRD) linked to Hospital Episode Statistics (HES). CPRD is a large, representative national primary 
care dataset containing anonymised medical records currently encompassing 42 million patient lives 
from over 1,700 primary care practices in the UK [18]. Information is routinely and prospectively 
recorded for each patient, including patient demographic information, details of consultations, tests 
and diagnoses, and medical prescriptions. HES is a database containing information on all admissions 
to NHS hospitals in England [19]. Clinical information relating to diagnoses and procedures are 
recorded using codes from the International Classification of Diseases, 10th revision (ICD-10) and 
UK Office of Population, Census and Surveys (OPCS) Classification of Interventions and Procedures 
version 4.6, respectively [20, 21]. Approximately 75% of active practices contributing to CPRD in 
England (58% of all UK practices) are linked with HES, thus providing additional secondary care 
clinical information for all patients from these practices [22]. We used linked HES data to improve 
the quality and accuracy of our data as information such as an infant’s birth weight and gestational 
age are often included in the mother’s hospital records. Both databases have been validated with other 
sources of information and are widely used for epidemiological research [22].  
 
Study population and exposure groups 
 
We included children born in English hospitals from April 1997 to May 2014 who were registered 
with a CPRD practice within six months of birth and had at least three months of follow-up data 
(Figure 1).  They were followed up from first registration in CPRD until either their fifth birthday, 31 
December 2014 (database extraction date) or when they left the general practice. We included all 
infants with a GA of 23+0 weeks to 43+6 weeks and with sex-specific birth weights from the 9th to 
91st centiles were included (94.9%) [23]. This avoided any erroneous entries with birth weight and the 
majority with abnormal growth patterns, as identification of babies with growth restriction was not 
possible from this dataset. The distribution of our study population was broadly similar to the 
population distribution for gestational age and birth weight released by the Office of National 
Statistics 2010 (Supplementary tables 1 and 2), considering CPRD underrepresents babies born at the 
extreme of prematurity as it includes only survivors who register with a general practice, whereas 
ONS data include all registered live births.   
 
For our primary analysis, we identified two cohorts of newborn infants: 1) term infants born ≥ 37 
completed weeks of gestation, with birth weights ≥2500g and without prescriptions for home oxygen 
(Term); and 2) preterm infants born before 32 completed weeks of gestation with birth weights 
<1500g (Preterm). The Preterm group were further divided into two cohorts for secondary sub-group 
analysis: those with (PT-O2) and without (PT-Air) home oxygen prescriptions in their medical records 





The primary outcomes were defined as a) rates of primary care consultations for three respiratory 
conditions - respiratory tract infection (RTI, including both upper and lower RTIs), lower respiratory 
tract infection specifically (LRTI), and wheeze; and b) rates of antibiotic prescriptions (Abx Px). 
Episodes of respiratory outcomes were identified using Read medical codes recorded in primary care 
records (available from the authors on request) [24, 25]. For example, an RTI was defined based on a 
recorded clinical diagnosis of a relevant infection (e.g. acute respiratory infection, acute pharyngitis) 
or an infection-related symptom (e.g. cough with fever, sore throat) during the follow-up period. As 
previously, we defined recovery as the 15th day after the initial diagnosis of infection [24, 25] with 
any subsequent diagnosis considered to be the same infection episode and the recovery date was 
extended to the 8th day of this recording (if later than original recovery date), to ensure each episode 
lasted at least 14 days.  
Antibiotic prescriptions were identified using Multilex drug codes (drug codes available from the 
authors on request). We included antibiotics detailed as suitable for treating respiratory infections, as 
defined by the British National Formulary for Children (BNFC) in the following classes: penicillins; 
cephalosporins and other beta-lactams; macrolides; and sulphonamides and trimethoprim [26].  
 
Other co-variables  
Data were extracted on descriptive characteristics and co-variables including sex, socioeconomic status 
measured using the Index of Multiple Deprivation (IMD) 2010 [27, 28], and presence of major 
congenital anomalies based on the European Surveillance of Congenital Anomalies (EUROCAT) 




Data management and analyses were undertaken using STATA version 14 (StataCorp, College 
Station, TX, USA).  The number of episodes of respiratory infection, antibiotic prescriptions and 
crude incidence rate (IR) per 10 person years with 95% confidence intervals (95% CI) were calculated 
both overall and separately for each covariable. We used negative binomial regression to generate 
incidence rate ratios (IRR) comparing preterm to term infants with adjustment for potential 
confounders, including yearly age bands, sex, IMD 2010 quintiles and presence of congenital 
anomalies.  
To examine the differences in outcomes between ex-preterm infants discharged home in air (PT-Air) 
and ex-preterm infants discharged on home oxygen (PT-O2), we repeated the above steps as further 
sub-group analyses and compared these results to their term counterparts.  
 
In addition, we conducted the analyses over two epochs to assess changes in respiratory morbidity 
over time. We divided the study period into two equal 8-year epochs: Epoch 1 (1997-2005) and 




The providers of the CPRD data received ethical approval from a National Research Ethics Service 
Committee (NRES) for data collection and subsequent observational research using anonymised data; 
individual studies using CPRD data do not require further separate ethical approval. The protocol for 








We identified 253,277 eligible children: 251,611 children in the term group and 1,666 children in the 
preterm group (Table 1). More children in the preterm group (44.9%) were from more deprived 
socioeconomic backgrounds (IMD 2010 fourth and fifth quintiles) compared to those in the term 
group (39.3%).   
 
 
Respiratory tract infections (RTI) 
 
The overall crude IR for consultations for RTI in the term and preterm groups were 7.17 (95% CI 
7.15-7.19) and 9.69 (95% CI 9.42-9.96) respectively. The aIRR for the preterm group was 1.37 (95% 
CI 1.33-1.42, p<0.001) after adjustment for confounding factors (Table 2, Figure 2). Both term and 
preterm groups had the highest IR of consultations for RTI within their first year of life, which 
gradually decreased over the first five years of childhood. However, the IR in the preterm group was 
significantly higher than the term group in all age groups (p<0.001). The highest IR of consultations 
for RTIs were found in the most socioeconomic deprived group (Supplementary table 3).  aIRRs were 
also increased for children in the preterm group compared to the term group (Supplementary table 3).  
Lower respiratory tract infections (LRTI) 
 
Children in the preterm group had a significantly higher overall IR for consultations for LRTI at 2.74 
(95% CI 2.60-2.89) compared to 1.14 in the term group (95% CI 1.13-1.15). After adjustments, the 
IRR for consultations for LRTI in the preterm group in the first five years of life was 2.79 (95% CI 
2.59-3.01, p<0.001) (Table 2). The rates of consultations for LRTI in the preterm group were 
consistently higher than those in the term group across all age groups, peaking in the second year of 
life before declining.  Consultations for LRTIs were the highest in the most deprived populations for 
both term and preterm infants.  As seen with consultations for RTI, all aIRRs were increased in the 




The overall IR of consultations for wheeze was more than double in the preterm cohort compared to 
the term cohort (Table 2), with an aIRR of 3.05 (95% CI 2.64-3.52, p<0.001).  Wheeze was more 
likely to be diagnosed in the first year of life for term infants but peaked in the second year of life for 
preterm infants. Rates of consultations for wheeze were significantly higher in the preterm population 
throughout all age groups and deprivation quintiles (Supplementary table 5).  
 
Antibiotic Prescriptions (Abx Px) 
 
Ex-preterm infants had significantly higher rates of Abx Px compared to their term counterparts with 
overall IR of 12.67 (95% CI 12.38-12.97) and 8.40 (95% CI 8.38-8.42) respectively (Table 2, Figure 
3). The aIRR for the preterm group was 1.49 (95% CI 1.44-1.55, p<0.001). Children in both cohorts 
had the highest rate of Abx Px in their second year of life before gradually decreasing.  There were no 
significant differences in prescribing based on socioeconomic background (Supplementary table 6).  




The PT-O2 group were more likely to have lower gestational ages compared to those in the PT-Air 
group (Table 3). There was a significant increase in morbidity across all three respiratory outcomes 
and Abx Px in the PT-O2 group compared to those in the PT-Air group (Table 4, Supplementary 
tables 8 and 9). Compared with the PT-Air group, the PT-O2 had higher aIRRs for consultations for 
RTI (1.21, 95% CI 1.12-1.30, p<0.001), LRTI (1.74, 95% CI 1.50-2.03, p<0.001) and Abx Px (1.39, 
95% CI 1.28-1.50, p<0.001). PT-O2 also had higher incidence rates for consultations for wheeze, 
however this was not statistically significant following adjustment. Rates of consultations for RTI and 
LRTI observed in the PT-O2 group were consistently higher than those in the PT-Air group across all 
age groups (Figure 3). In particular, the rate of consultations for LRTI seen in the PT-O2 group was 




The study cohort was divided into two 8-year epochs: Epoch 1 (1997-2005) included 87,556 children 
and Epoch 2 (2006-2014) included 165,721 children (Supplementary Table 10). Overall, there were 
no substantial differences in the aIRRs for consultations for RTI, LRTI, and wheeze between two 
epochs; the 95% confidence intervals for the two epochs for these outcomes overlap (Table 5). The 





This study, based on a large nationally representative sample of young children in England, highlights 
a vulnerable cohort of ex-preterm children with significant respiratory morbidity in early childhood 
compared to children born at term. Ex-preterm infants had higher rates of primary care diagnosed 
respiratory infections especially LRTI which are more likely to result in the need for antibiotics [30]. 
For ex-preterm infants discharged on home oxygen, the rates of consultations for LRTI and Abx Px 
are even greater and remain high throughout childhood and never fall below that of term babies across 
all years.   
 
Prematurity and low birth weight were associated with a persistent increase in respiratory morbidity in 
early childhood. This appeared magnified for the infants in the PT-O2 cohort who had significantly 
worse respiratory outcomes compared to those in the PT-Air cohort. The rates of consultations for 
RTI seen in our study are higher than those previously reported [31], however those were reported 
from hospital admissions for respiratory conditions. The highest rates of infection-related 
consultations were mostly observed in the first year of life when innate immune responses 
predominate, in keeping with other large hospital-based epidemiological studies previously published 
[32]. These infective episodes were more common in both the more deprived term and preterm groups 
confirming the adverse impact of social deprivation on child respiratory health.  
 
Our study highlights the significant respiratory burden presenting to primary care in ex-preterm 
infants, especially those discharged on home oxygen who are more likely to have severe BPD.  There 
is a paucity of data in this population and the rates of presentation to primary care.  A number of small 
studies have focused on the respiratory function of these ex-preterm infants rather than the clinical 
burden in the community. The long-term respiratory function of ex-preterm infants has previously 
been reported whereby childhood impairment of lung function is a significant predictor of abnormal 
longitudinal patterns of lung-function growth and decline into adulthood [33]. Gough et al and Yang 
et al have reported persistent adult respiratory morbidity in ex-preterm infants with BPD including 
more significant impairment of lung function and increased respiratory symptoms [12, 34].  
 
As extreme preterm survival and BPD continue to rise, along with the associated lifelong respiratory 
morbidity, it is extremely important to explore key periods in early life amenable to interventions to 
improve long-term respiratory health.  It is unclear who is best placed to manage and support the 
respiratory health of these children following discharge from the neonatal unit. The high rates of 
consultations for LRTI and Abx Px in the PT-O2 group would suggest these children may benefit 
from expert paediatric respiratory follow-up.  In our study we are unable to ascertain which children 
had such follow-up but a previous study suggests less than 20% of extremely preterm children with 
moderate/severe BPD have paediatric follow-up at six years of age [35]. In the UK, British Thoracic 
Society (BTS) guidelines for home oxygen recommend that infants should have hospital follow-up 
either at a tertiary centre, or district general hospital if the general paediatrician has experience of 
home oxygen [14]. As respiratory physicians have the specialty expertise in managing and optimising 
lung health, it is currently unclear if targeted paediatric respiratory follow-up would reduce 
respiratory morbidity in this cohort of children; an approach the Prematurity and Respiratory 
Outcomes Program (PROP) in the US has identified with the need for integrated, multidisciplinary 
research and clinical teams [36]. 
 
Our study aimed to report on primary care consultations where general practitioners (GPs) make the 
clinical diagnosis of infection and decide if antibiotics are indicated. Higher levels of anxiety amongst 
parents with ex-preterm infants may lead to increased health-seeking behaviour [37]. Equally, GPs 
may also be more anxious about this cohort of children given their clinical history or co-morbidities 
and so have lower thresholds to prescribe antibiotics for such infections. These could contribute to the 
high rates of Abx Px seen prescribed to both preterm cohorts in our study. Antimicrobial resistance is 
a serious global concern at a time when prescribing antibiotics is at an all-time high [38], therefore 
additional parental education and support for GPs could help improve antimicrobial stewardship in 
these children.  
 
Our study is the largest to date, from a robust and well validated data source [22], quantifying a 
previously unrecorded burden of primary healthcare utilisation and respiratory morbidity in a recent 
ex-preterm population. Previous studies in this population have focused on hospital admissions only 
or did not allow comparison between preterm infants discharged with or without home oxygen and  
term infants in the same population [15, 31].   
There appears to be no significant differences over the study time period as observed by the epoch 
analysis with consultations for infection and wheeze rate differences between term and preterm 
unchanged.  Abx Px rates remain higher for the preterm population although the difference appears 
slightly lower in recent years.  The reasons for this are unclear, especially with similar rates of 
infection being diagnosed, but are perhaps related to better antibiotic stewardship, smaller numbers in 
the preterm groups as a consequence of epoch division, or other mechanisms not measured in this 
study. 
 
There are a number of limitations of this study including the retrospective nature, although data were 
collected prospectively. The lack of paired respiratory diagnosis and Abx Px makes it difficult to 
directly link these episodes although we only included antibiotics which may be used for respiratory 
infections. Some of these drugs could be used for other infections, for example, trimethoprim is used 
for urinary tract infections. The database analysis does not allow us to classify which preterm children 
had a diagnosis of BPD. We therefore used home oxygen as a proxy for more severe respiratory 
disease although this requirement can be related to morbidities, other than BPD, or other factors we 
haven’t modelled such as GA. Prospective data on which specialists undertake outpatient follow-up of 
the preterm group would also help understand any impact on respiratory morbidity.  The present study 
focused on primary care consultations which have not been studied in such detail. Extension of this 
study to include hospital attendances was beyond the scope of this study but could be useful 
supporting the morbidity observed as previously reported [31, 39]. 
 
Finally, we also had no data on children’s exposure to cigarette smoke, either in-utero or passive 
exposure during childhood. Recording of smoking status of pregnant women in primary care data is 
incomplete [40] and data recorded may not accurately reflect women’s true smoking status. 
Nevertheless, we acknowledge the impact of maternal smoking on health and lung function, including 
the increasing prevalence of childhood respiratory infections and wheeze [36].  As smoking is more 
prevalent in lower socioeconomic populations this could contribute to some of the additional 





Our findings highlight significant respiratory morbidity in ex-preterm infants, especially those 
discharged home on oxygen and likely to have more severe BPD, in the first five years of life. With 
increasing survival and BPD in this population there could be an increased health resources 
implication for both hospital physicians and GPs.  Additional research is needed on prevention 
strategies to minimise respiratory morbidity and improve long-term lung function for these high-risk 
children. Key to this is the identification of core respiratory outcomes most important for both 
clinicians and parents, and for targeted interventions to ameliorate these. Longer term respiratory 
follow up is essential as more of these vulnerable infants survive to reduce the burden for children, 
their families and healthcare services.  Who is best placed to undertake long-term respiratory follow-
up remains to be established.   
Table 1: Baseline characteristics of children in study   
Characteristics 
Term: ≥37/40  
and ≥2500 g 
N = 251,611 
Preterm: <32/40  
and <1500 g 
N = 1,666 
p-value  
Male sex, n (%) 130,220 (51.8) 815 (48.9) 0.021 
Gestational age at birth (weeks), median (IQR) 
 
40 (39-41) 28 (27-30) <0.001 
Birth weight in g, median (IQR) 
 
3459 (3180-3745) 1168 (966-1330) <0.001 
IMD 2010 quintile, n (%)  
1 (least deprived) 54,154 (21.5) 280 (16.8) <0.001 
2 51,410 (20.4) 330 (19.8) 
3 46,687 (18.6) 305 (18.3) 
4 49,899 (19.8) 364 (21.9) 
5 (most deprived) 49,071 (19.5) 383 (23.0) 
Missing  390 (0.2) 4 (0.2) 
Age at the beginning of follow up in days,            
 median (IQR) 
25 (14-43) 49 (29-75) <0.001 
Length of follow-up in months,  
 median (IQR) 
 
48 (24-60) 49 (23-60) <0.001 
Congenital anomalies, n (%) 6,158 (2.5) 333 (20) <0.001 
 
 
Table 2: Overall incidence rates and incidence rate ratios (unadjusted and adjusted) for respiratory 
outcomes in the first five years of life in term and preterm cohorts 
 



















































All rates are described as per 10 person years; CI= confidence interval; IRR= incidence rate ratio; 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; **p-value < 0.001 
 
Table 3: Baseline characteristics of preterm children with (PT-O2) and without (PT-Air) home oxygen 
Characteristics 
PT-Air 
(N = 1,217) 
PT-O2 
(N = 449) 
Male sex, n (%) 575 (47.2) 240 (53.5) 
Gestational age at birth (weeks), median (IQR) 
 
29 (28-30) 26 (25-28) 
Birth weight in g, median (IQR) 
 
1245 (1077-1360) 955 (794-1095) 
IMD 2010 quintile, n (%) 
1 (least deprived) 207 (17.0) 73 (16.3) 
2 235 (19.3) 95 (21.2) 
3 231 (19.0) 74 (16.5) 
4 259 (21.3) 105 (23.4) 
5 (most deprived) 284 (23.3) 99 (22.0) 
Missing 1 (0.1) 3 (0.6) 
Congenital anomalies, n (%) 175 (14.4) 158 (35.2) 
 
 
Table 4: Overall incidence rates and incidence rate ratios (unadjusted and adjusted) for respiratory 
outcomes in the first five years of life PT-Air and PT-O2 cohorts 
 



















































All rates are described as per 10 person years; CI= confidence interval; IRR= incidence rate ratio; 










Table 5: Epoch analyses showing unadjusted and adjusted IRRs between term and preterm cohorts  
 
 









RTI 1.34** (1.28-1.40) 1.36** (1.29-1.43) 1.36** (1.31-1.42) 1.37** (1.30-1.43) 
LRTI 2.24** (2.07-2.43) 2.64** (2.36-2.96) 2.50** (2.33-2.69) 2.81** (2.55-3.11) 
Wheeze 1.95** (1.71-2.22) 2.48** (1.98-3.10) 2.60** (2.34-2.88) 3.36** (2.79-4.05) 
Abx Px 1.52** (1.47-1.58) 1.58** (1.50-1.67) 1.49** (1.44-1.54) 1.41** (1.34-1.48) 
# Adjusted for age, sex, IMD 2010 quintile, congenital abnormalities; **p-value < 0.001
Figure 1: Flow diagram illustrating the number of children included and excluded from the cohort at 






Figure 2: Overall adjusted IRRs for respiratory outcomes comparing term and preterm cohorts over 






Figure 3: Crude incidence rates of respiratory outcomes (RTI, LRTI, wheeze) and Abx Px across all 
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Supplementary Table 1: Distribution of our study population according to gestational age in comparison to Office for National Statistics (ONS) data 2010.  







Redefined CPRD population, 
n (%) 
<24 750 (0.11) 112 (0.04) 
24-27 2,329 (0.33) 3706 (1.28) 
28-31 5,757 (0.81) 5,552 (1.92) 
32-36 41,914 (5.89) 19,342 (6.70) 
37-42 630,797 (88.64) 259,148 (89.79) 
Post-term, >42 30,065 (4.22) 753 (0.26) 




Supplementary Table 2: Distribution of our study population according to birthweight in comparison to Office for National Statistics (ONS) data 2010. ONS 






Redefined CPRD population, 
n (%) 
<1000 4,170 (0.58) 586 (0.20) 
1000-1499 4,591 (0.64) 1,883 (0.65) 
1500-2499 41,484 (5.82) 18,977 (6.58) 
2500-3999 581,253 (81.50) 239,041 (82.82) 
>4000 81,759 (11.46) 28,126 (9.75) 
Total 713,257 288,613 
 
  
Supplementary Table 3: Incidence rates and incidence rate ratios of respiratory tract infections (RTI) between groups of children  
 
 





Rate per 10 person years 
(95% CI) 
Events 








Overall 451,438 7.17 (7.15-7.19) 4,940 9.69 (9.42-9.96) 1.35 (1.31-1.39) <0.001 1.37 (1.33-1.42) <0.001 
Age (years) 
0-1 172,887 10.17 (10.13-10.22) 1,601 12.65 (12.05-13.29) 1.24 (1.18-1.31) <0.001 1.21 (1.15-1.28) <0.001 
1-2 126,278 8.09 (8.04-8.13) 1,463 11.66 (11.07-12.27) 1.44 (1.37-1.52) <0.001 1.50 (1.40-1.61) <0.001 
2-3 70,146 5.60 (5.56-5.65) 886 8.70 (8.14-9.29) 1.55 (1.45-1.66) <0.001 1.59 (1.45-1.75) <0.001 
3-4 49,911 4.99 (4.96-5.04) 595 7.01 (6.47-7.6) 1.40 (1.29-1.53) <0.001 1.41 (1.26-1.57) <0.001 
4-5 32,216 4.09 (4.05-4.14) 395 5.56 (5.03-6.13) 1.36 (1.23-1.50) <0.001 1.36 (1.19-1.57) <0.001 
Sex         
Male 245,307 7.53 (7.50-7.56) 2,464 10.0 (9.61-10.4) 1.33 (1.28-1.38) <0.001 1.33 (1.27-1.40) <0.001 
Female 206,131 6.78 (6.75-6.81) 2,476 9.40 (9.03-9.77) 1.39 (1.33-1.44) <0.001 1.42 (1.35-1.49) <0.001 
IMD 2010 quintile     
1 (least 
deprived) 
98,082 7.14 (7.10-7.18) 803 8.77 (8.19-9.40) 1.23 (1.14-1.32) <0.001 1.25 (1.15-1.36) <0.001 
2 90,665 6.99 (6.95-7.04) 1,020 9.44 (8.88-10.04) 1.35 (1.27-1.44) <0.001 1.37 (1.27-1.48) <0.001 
3 81,032 7.01 (6.96-7.06) 879 9.58 (8.96-10.23) 1.37 (1.28-1.46) <0.001 1.43 (1.32-1.55) <0.001 
4 89,677 7.19 (7.15-7.24) 1,068 10.09 (9.50-10.72) 1.40 (1.32-1.49) <0.001 1.41 (1.30-1.52) <0.001 
5 (most 
deprived) 
91,274 7.51 (7.46-7.56) 1,157 10.39 (9.80-11.00) 1.38 (1.30-1.47) <0.001 1.40 (1.30-1.51) <0.001 
Missing 708 7.84 (7.28-8.44) 13 9.99 (5.80-17.20) 1.27 (0.67-2.19) 0.19 1.07 (0.55-2.09) 0.84 
Congenital anomalies (CA)     
No CA 437,238 7.13 (7.11-7.15) 3,805 9.39 (9.09-9.69) 1.32 (1.28-1.36) <0.001 1.40 (1.35-1.45) <0.001 
Has CA 14,200 8.69 (8.55-8.84) 1,135 10.86 (10.24-11.51) 1.25 (1.17-1.33) <0.001 1.28 (1.19-1.38) <0.001 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio 
Supplementary Table 4: Incidence rates and incidence rate ratios of lower respiratory tract infections (LRTI) between groups of children 
 





Rate per 10 person years 
(95% CI) 
Events 








Overall 71,929 1.14 (1.13-1.15) 1,397 2.74 (2.60-2.89) 2.40 (2.27-2.53) <0.001 2.79 (2.59-3.01) <0.001 
Age (years) 
0-1 29,630 1.74 (1.72-1.76) 520 2.36 (2.16-2.57) 2.36 (2.16-2.57) <0.001 2.36 (2.13-2.61) <0.001 
1-2 20,645 1.32 (1.30-1.34) 422 3.36 (3.06-3.70) 2.54 (2.30-2.80) <0.001 3.61 (3.02-4.32) <0.001 
2-3 10,753 0.86 (0.84-0.88) 227 2.23 (1.96-2.54) 2.59 (2.26-2.96) <0.001 3.39 (2.71-4.24) <0.001 
3-4 6,794 0.68 (0.66-0.70) 145 1.71 (1.45-2.01) 2.51 (2.11-2.96) <0.001 3.36 (2.55-4.43) <0.001 
4-5 4,107 0.52 (0.51-0.54) 83 1.17 (0.94-1.45) 2.24 (1.78-2.78) <0.001 2.52 (1.79-3.54) <0.001 
Sex         
Male 41,097 1.26 (1.25-1.27) 701 2.84 (2.64-3.06) 2.26 (2.09-2.43) <0.001 2.59 (2.33-2.88) <0.001 
Female 30,832 1.01 (1.00-1.03) 696 2.64 (2.45-2.85) 2.60 (2.41-2.81) <0.001 3.01 (2.71-3.35) <0.001 
IMD 2010 quintile     
1 (least 
deprived) 
15,486 1.13 (1.11-1.15) 232 2.53 (2.23-2.88) 2.25 (1.97-2.56) <0.001 2.58 (2.16-3.08) <0.001 
2 14,261 1.10 (1.08-1.12) 286 2.65 (2.36-2.97) 2.41 (2.13-2.71) <0.001 2.82 (2.39-3.33) <0.001 
3 12,748 1.10 (1.08-1.12) 235 2.56 (2.25-2.91) 2.32 (2.03-2.64) <0.001 2.77 (2.31-3.33) <0.001 
4 14,344 1.15 (1.13-1.17) 290 2.74 (2.44-3.07) 2.38 (2.11-2.68) <0.001 2.70 (2.28-3.19) <0.001 
5 (most 
deprived) 
14,989 1.23 (1.21-1.25) 349 3.13 (2.82-3.48) 2.54 (2.28-2.83) <0.001 3.03 (2.60-3.53) <0.001 
Missing 101 1.12 (0.92-1.36) 5 3.84 (1.60-9.28) 3.43 (1.09-8.28) 0.01 3.61 (0.78-16.77) 0.10 
Congenital anomalies (CA)     
No CA 69,240 1.13 (1.12-1.14) 1,029 2.54 (2.39-2.70) 2.25 (2.11-2.39) <0.001 2.84 (2.61-3.09) <0.001 
Has CA 2,689 1.64 (1.59-1.71) 368 3.52 (3.18-3.90) 2.14 (1.91-2.39) <0.001 2.60 (2.22-3.03) <0.001 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio 
Supplementary Table 5: Incidence rates and incidence rate ratios of wheeze between groups of children 
 
 





Rate per 10 person 
years (95% CI) 
Events 








Overall 32,529 0.52 (0.51-0.52) 608 1.19 (1.10-1.29) 2.31 (2.13-2.50) <0.001 3.05 (2.64-3.52) <0.001 
Age (years) 
0-1 13,336 0.78 (0.77-0.80) 218 1.72 (1.51-1.97) 2.20 (1.91-2.51) <0.001 2.33 (1.93-2.81) <0.001 
1-2 9,695 0.62 (0.61-0.63) 234 1.86 (1.64-2.12) 3.00 (2.63-3.42) <0.001 5.97 (4.27-8.36) <0.001 
2-3 4,858 0.39 (0.38-0.40) 92 0.90 (0.74-1.11) 2.33 (1.87-2.86) <0.001 3.88 (2.41-6.25) <0.001 
3-4 3,016 0.30 (0.29-0.31) 40 0.47 (0.35-0.64) 1.56 (1.11-2.13) 0.004 1.60 (0.96-2.68) 0.07 
4-5 1,624 0.21 (0.20-0.22) 24 0.34 (0.23-0.50) 1.64 (1.05-2.44) 0.01 2.00 (0.98-4.07) 0.06 
Sex         
Male 20,813 0.64 (0.63-0.65) 371 1.51 (1.36-1.67) 2.36 (2.12-2.61) <0.001 3.04 (2.51-3.67) <0.001 
Female 11,716 0.39 (0.38-0.39) 237 0.90 (0.79-1.02) 2.33 (2.04-2.65) <0.001 3.18 (2.51-4.02) <0.001 
IMD 2010 quintile     
1 (least 
deprived) 
7,358 0.54 (0.52-0.55) 102 1.11 (0.92-1.35) 2.08 (1.69-2.53) <0.001 2.49 (1.76-3.52) <0.001 
2 6,522 0.50 (0.49-0.52) 135 1.25 (1.06-1.48) 2.48 (2.08-2.95) <0.001 3.37 (2.46-4.63) <0.001 
3 5,835 0.50 (0.49-0.52) 108 1.18 (0.97-1.42) 2.33 (1.91-2.82) <0.001 3.23 (2.29-4.56) <0.001 
4 6,101 0.49 (0.48-0.50) 106 1.00 (0.83-1.21) 2.05 (1.67-2.48) <0.001 2.52 (1.82-3.48) <0.001 
5 (most 
deprived) 
6,648 0.55 (0.53-0.56) 156 1.40 (1.20-1.64) 2.56 (2.17-3.00) <0.001 3.77 (2.83-5.04) <0.001 
Missing 65 0.72 (0.56-0.92) 1 0.77 (0.11-5.45) 1.07 (0.03-6.16) 0.43 1.09 (0.05-24.11) 0.96 
Congenital anomalies (CA)     
No CA 31,456 0.51 (0.51-0.52) 443 1.09 (1.00-1.20) 2.13 (1.94-2.34) <0.001 2.99 (2.53-3.52) <0.001 
Has CA 1,073 0.66 (0.62-0.70) 165 1.58 (1.36-1.84) 2.40 (2.03-2.83) <0.001 3.37 (2.56-4.45) <0.001 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio 
Supplementary Table 6: Incidence rates and incidence rate ratios of antibiotic prescriptions between groups of children  
 
 





Rate per 10 person 
years (95% CI) 
Events 








Overall 711,743 8.40 (8.38-8.42) 6,971 12.67 (12.38-12.97) 1.51 (1.47-1.54) <0.001 1.49 (1.44-1.55) <0.001 
Age (years) 
0-1 180,426 8.15 (8.11-8.19) 1,401 10.30 (9.77-10.85) 1.26 (1.20-1.33) <0.001 1.14 (1.07-1.22) <0.001 
1-2 212,120 10.29 (10.25-10.34) 2,155 15.96 (15.30-16.65) 1.55 (1.49-1.62) <0.001 1.55 (1.45-1.66) <0.001 
2-3 135,874 8.06 (8.01-8.10) 1,475 13.36 (12.69-14.05) 1.66 (1.57-1.74) <0.001 1.75 (1.60-1.90) <0.001 
3-4 108,033 7.82 (7.77-7.86) 1,113 12.11 (11.42-12.85) 1.55 (1.46-1.64) <0.001 1.53 (1.39-1.68) <0.001 
4-5 75,290 6.68 (6.63-6.72) 827 10.76 (10.05-11.52) 1.61 (1.50-1.73) <0.001 1.66 (1.48-1.86) <0.001 
Sex         
Male 389,818 8.89 (8.86-8.91) 3,692 13.76 (13.32-14.21) 1.55 (1.50-1.60) <0.001 1.54 (1.46-1.62) <0.001 
Female 321,925 7.88 (7.85-7.91) 3,279 11.63 (11.24-12.04) 1.48 (1.43-1.53) <0.001 1.45 (1.37-1.53) <0.001 
IMD 2010 quintile     
1 (least 
deprived) 
161,597 8.40 (8.36-8.44) 1,266 12.83 (12.14-13.55) 1.53 (1.44-1.61) <0.001 1.70 (1.56-1.86) <0.001 
2 147,517 8.35 (8.31-8.39) 1,397 12.43 (11.80-13.55) 1.49 (1.41-1.57) <0.001 1.48 (1.36-1.61) <0.001 
3 129,433 8.36 (8.31-8.41) 1,267 12.48 (11.82-13.19) 1.49 (1.41-1.58) <0.001 1.43 (1.31-1.55) <0.001 
4 138,038 8.49 (8.45-8.54) 1,530 13.34 (12.69-14.02) 1.57 (1.49-1.65) <0.001 1.49 (1.38-1.61) <0.001 
5 (most 
deprived) 
134,113 8.40 (8.36-8.45) 1,500 12.33 (11.72-12.97) 1.47 (1.39-1.54) <0.001 1.42 (1.32-1.54) <0.001 
Missing 1,045 8.81 (8.29-9.36) 11 8.45 (4.68-15.26) -0.04 (-0.54-0.47) 0.46 0.64 (0.30-1.38) 0.26 
Congenital anomalies (CA)     
No CA 679,215 8.24 (8.22-8.26) 5,203 11.87 (11.55-12.19) 1.44 (1.40-1.48) <0.001 1.65 (1.58-1.72) <0.001 
Has CA 32,528 14.42 (14.26-14.58) 1,768 15.82 (15.10-16.57) 1.10 (1.05-1.15) <0.001 1.06 (0.98-1.15) 0.13 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio 





Term PT-Air PT-O2 
 
Events 
Rate per 10 person years 
(95% CI) 
Events 
Rate per 10 person years 
(95% CI) 
Events 
Rate per 10 person years 
(95% CI) 
Overall 711,743 8.40 (8.38-8.42) 4,768 11.63 (11.31-11.97) 2,203 15.71 (15.06-16.38) 
Class of antibiotics 
Broad-spectrum penicillins 
 
704,503 8.32 (8.30-8.34) 4,496 10.97 (10.65-11.29) 1,923 13.71 (13.11-14.34) 
Macrolides 
 
138,507 1.64 (1.63-1.64) 956 2.33 (2.19-2.48) 415 2.96 (2.69-3.26) 
Benzylpenicillin and 
phenoxymethylpenicillin 
97,269 1.15 (1.14-1.16) 411 1.00 (0.91-1.10) 160 1.14 (0.98-1.33) 
Penicillinase-resistant 
penicillins 
62,918 0.74 (0.74-0.75) 272 0.66 (0.59-0.75) 77 0.55 (0.44-0.69) 
Sulphonamides and 
trimethoprim 
52,317 0.62 (0.61-0.62) 469 1.14 (1.05-1.25) 223 1.59 (1.39-1.81) 
Cephalosporins 
 
33,356 0.39 (0.39-0.40) 315 0.77 (0.69-0.86) 204 1.45 (1.27-1.67) 
Supplementary Table 8: Incidence rate ratios of consultations for lower respiratory tract infections (LRTI) and antibiotic prescriptions (Abx Px) between 




Lower Respiratory Tract Infections  Antibiotic Prescriptions (Abx Px) 
















Overall 1.65 (1.48-1.85) <0.001 1.74 (1.50-2.03) <0.001 1.35 (1.28-1.42) <0.001 1.39 (1.28-1.50) <0.001 
Age         
0-1 1.46 (1.21-1.75) <0.001 1.39 (1.14-1.69) 0.001 1.15 (1.02-1.29) 0.009 1.12 (0.96-1.31) 0.14 
1-2 1.56 (1.27-1.91) <0.001 1.63 (1.19-2.25) 0.003 1.35 (1.24-1.48) <0.001 1.32 (1.15-1.52) <0.001 
2-3 2.03 (1.55-2.67) <0.001 2.65 (1.77-3.96) <0.001 1.43 (1.28-1.60) <0.001 1.51 (1.26-1.82) <0.001 
3-4 1.61 (1.12-2.28) 0.004 1.81 (1.02-3.23) 0.04 1.43 (1.26-1.62) <0.001 1.73 (1.40-2.14) <0.001 
4-5 2.31 (1.45-3.64) <0.001 2.58 (1.38-4.83) 0.003 1.38 (1.19-1.61) <0.001 1.38 (1.07-1.78) 0.01 
Sex         
Male 1.87 (1.60-2.18) <0.001 2.12 (1.73-2.61) <0.001 1.45 (1.36-1.55) <0.001 1.65 (1.49-1.83) <0.001 
Female 1.44 (1.22-1.69) <0.001 1.43 (1.15-1.78) 0.001 1.21 (1.12-1.30) <0.001 1.33 (1.18-1.49) <0.001 
IMD 2010 quintile     
1 (least 
deprived) 
1.66 (1.26-2.18) <0.001 1.82 (1.29-2.56) 0.001 1.57 (1.40-1.77) <0.001 2.17 (1.77-2.65) <0.001 
2 1.60 (1.25-2.04) <0.001 1.57 (1.11-2.22) 0.01 1.25 (1.12-1.40) <0.001 1.25 (1.04-1.51) 0.02 
3 1.88 (1.42-2.48) <0.001 2.27 (1.57-3.27) <0.001 1.34 (1.18-1.52) <0.001 1.38 (1.15-1.66) 0.001 
4 1.64 (1.28-2.09) <0.001 1.61 (1.19-2.20) 0.002 1.20 (1.07-1.34) <0.001 1.06 (0.90-1.26) 0.48 
5 (most 
deprived) 
1.54 (1.23-1.93) <0.001 1.64 (1.21-2.23) 0.002 1.46 (1.31-1.63) <0.001 1.42 (1.21-1.67) <0.001 
Missing . 0.05 . . 0.99 (0.25-4.63) 0.49 1.01 (0.22-4.66) 0.99 
Congenital anomalies     
No CA 1.57 (1.37-1.79) <0.001 1.78 (1.49-2.14) <0.001 1.20 (1.13-1.28) <0.001 1.31 (1.19-1.44) <0.001 
Has CA 1.61 (1.30-1.99) <0.001 1.66 (1.28-2.15) <0.001 1.46 (1.33-1.61) <0.001 1.58 (1.37-1.82) <0.001 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio  




Respiratory Tract Infections (RTI) Wheeze 
















Overall 1.22 (1.15-1.3) <0.001 1.21 (1.12-1.30) <0.001 1.18 (0.99-1.41) 0.03 1.10 (0.86-1.42) 0.45 
Age         
0-1 1.05 (0.94-1.18) 0.17 1.04 (0.93-1.16) 0.52 0.91 (0.65-1.24) 0.27 0.84 (0.61-1.15) 0.28 
1-2 1.26 (1.12-1.40) <0.001 1.24 (1.07-1.45) 0.004 1.22 (0.91-1.62) 0.08 1.16 (0.69-1.96) 0.57 
2-3 1.23 (1.06-1.42) 0.003 1.24 (1.03-1.50) 0.02 1.75 (1.12-2.71) 0.01 1.81 (0.85-3.86) 0.12 
3-4 1.37 (1.15-1.63) <0.001 1.49 (1.17-1.90) 0.001 1.09 (0.49-2.25) 0.39 1.21 (0.59-2.48) 0.60 
4-5 1.43 (1.15-1.77) <0.001 1.65 (1.21-2.25) 0.002 1.24 (0.44-3.15) 0.31 1.16 (0.38-3.53) 0.80 
Sex         
Male 1.28 (1.18-1.39) <0.001 1.28 (1.16-1.42) <0.001 1.11 (0.88-1.39) 0.18 0.96 (0.70-1.31) 0.79 
Female 1.15 (1.05-1.26) 0.001 1.13 (1.01-1.27) 0.03 1.24 (0.92-1.65) 0.07 1.40 (0.90-2.19) 0.13 
IMD 2010 quintile     
1 (least 
deprived) 
1.12 (0.96-1.31) 0.07 1.17 (0.98-1.41) 0.09 1.24 (0.79-1.91) 0.16 1.53 (0.83-2.82) 0.17 
2 1.15 (1.00-1.32) 0.02 1.12 (0.94-1.33) 0.20 1.37 (0.94-1.97) 0.04 1.03 (0.62-1.70) 0.91 
3 1.49 (1.28-1.73) <0.001 1.65 (1.37-1.98) <0.001 1.16 (0.71-1.82) 0.26 1.15 (0.64-2.06) 0.64 
4 1.18 (1.04-1.34) 0.01 1.14 (0.98-1.34) 0.01 1.77 (1.18-2.65) 0.002 1.68 (0.98-2.90) 0.06 
5 (most 
deprived) 
1.21 (1.07-1.38) 0.001 1.14 (0.98-1.33) 0.09 0.75 (0.50-1.11) 0.07 0.61 (0.33-1.10) 0.10 
Missing 1.89 (0.49-10.70) 0.17 0.58 (0.04-9.14) 0.70 . . . . 
Congenital anomalies     
No CA 1.15 (1.06-1.23) <0.001 1.16 (1.06-1.27) 0.001 1.08 (0.85-1.35) 0.26 1.15 (0.84-1.57) 0.40 
Has CA 1.32 (1.17-1.48) <0.001 1.33 (1.16-1.53) <0.001 1.11 (0.81-1.52) 0.25 1.02 (0.69-1.52) 0.92 
# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio 








Term, n (%) 86,925 (99.2) 164,686 (99.4) 251,611 
PT-Air, n (%) 496 (0.6) 721 (0.4) 1,217 
PT-O2, n (%) 135 (0.2) 314 (0.2) 449 
Total 87,556 165,721 253,277 
 
 
 
 
